Study results indicate that mutation strength may shape both tumor–immune system interactions and immunotherapy response.
A retrospective analysis of 1,804 patients with NSCLC undergoing next-generation sequencing (NGS) in 2019-2024 at University Hospital Würzburg (single-center cohort, including 15 patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results